Getting your ADCs to the clinic: Consideration for early stage development

Dec 2, 2013, 8:30AM to 1:30PM

Location Coram Street
London, UK
Cost £599
Details The development of existing or novel monoclonal antibodies as drug-conjugates to increase the targeted clinical effect of these proteins has rapidly increased in recent years. Over 30 antibody–drug conjugates (ADCs) are being tested in the clinic in a range of oncology indications.

SMi's masterclass hosted by PAREXEL International will discuss ADCs which are being tested in the clinic in a range of oncology indications. In the absence of specific guidance on the development of ADCs, this workshop aims to help participants understand the CMC issues during the development, with a particular focus on the assessment and control of the quality of such products.

Contact Fateja Begum
Tel: +44 (0) 20 7827 6184
Email: fbegum@smi-online.co.uk

URLs:

Booking: http://atnd.it/17RSStC

Keywords: clinical studies, phase i, legistlations, cmc, conjugate, antibody, adc, antibody drug conjugate, eu, drug, regulatory, compliance, pharma, workshop, development, strategies.
Venue Holiday Inn Bloomsbury

add to calendar Add to Calendar
iCal | Outlook

 Return to Media Events